Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

In this study, researchers examined the under-studied mechanisms behind specific dermatological phenomena such as co-localization, Wolf's isotopic phenomenon, Koebner's isomorphic phenomenon, and the recently described Renbök phenomenon, noting that only a few cases have been reported so far.

This study suggests that 5α-reductase inhibitors do not significantly affect male reproductive function but may require caution in men with oligospermia or ejaculatory issues.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

In this study, exposure to ARBs, ACE inhibitors, and thiazides was associated with an increased risk of various skin cancers, including melanoma and nonmelanoma types, highlighting potential clinical implications for antihypertensive treatment choices.

The Androgen Receptor could be a target for treating diseases like cancer, but more research is needed to confirm the effectiveness of potential treatments.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

Upadacitinib effectively treats pyoderma gangrenosum.

In this study, upadacitinib was reported as effective in rapidly treating psoriasiform eczema in five male patients and showed varying degrees of effectiveness on other immune-mediated comorbidities like alopecia areata, vitiligo, ulcerative colitis, and hidradenitis suppurativa.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

In this study, TyroSpheres were used to encapsulate adapalene, increasing its solubility and enhancing skin distribution while reducing irritancy compared to a commercial formulation, indicating promise for acne treatment in ex vivo and in vitro settings.

In this study of Danioninae species, researchers reported that the presence of breeding tubercles on the pectoral fins is conserved in certain species and linked to local androgen conversion, with steroid 5-α-reductase playing a crucial role in their development.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study suggests that variations in CAG repeat numbers in the androgen receptor gene may not significantly influence the risk of androgenetic alopecia in Korean males.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

This study reports that a new artificial skin system using multi-layered hydrogels can promote scarless wound healing and regenerate appendages like hair follicles without cell transplantation.

This study found that patients with RASopathies have lower serum IgA and CD8 levels compared to controls, indicating a potential risk for developing autoimmune disorders.

This study found that the antiandrogen drug enzalutamide reduced TMPRSS2 levels and significantly decreased SARS-CoV-2 entry and infection in lung cells, supporting further clinical trials for COVID-19 treatment.

This study found that Ageratum conyzoides extract enhanced hair growth in mice and human follicle cells, showing potential for hormonal modulation, pathway activation, and antioxidant protection; however, further clinical studies are needed to confirm efficacy in humans.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

This study found that in prodromal Alzheimer's disease, pro-inflammatory gut bacteria were associated with reduced cerebral blood flow and reactivity, while beneficial gut bacteria correlated with better outcomes.

This study found that RALF peptides, through liquid-liquid phase separation, form condensates with pectin and other proteins, playing a pivotal role in plant development and stress response regulation.

This study investigated the potential mechanisms of Curcuma aeruginosa in treating androgenetic alopecia and identified 66 bioactive compounds interacting with proteins involved in the disorder, suggesting its involvement in hormone response and specific signaling pathways.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

Abatacept may help some people with alopecia areata regrow hair.